Effect of Anti CD20 in Pemphigus Desease

University Hospital, Rouen22 enrolled

Overview

to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Pemphigus

Interventions

MabtheraDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age\>18 * pemphigus corticoresistant * pemphigus cortico dependant * contre-indications : systémic steroids Exclusion Criteria: * age \< 18 * cardiopathie * pregnant woman * absence contraception * no consentment

Locations (1)

UH-Rouen

Rouen, Seine maritime, France

Outcomes

Primary Outcomes

primary end-point was the rate of CR three months after the last infusion of Rituximab

Secondary Outcomes

secondary end-points were :

rate of CR during the study period

time from the start of Rituximab to CR

number and length of time to relapses

treatment tolerance

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.